

# Cognetivity Neurosciences Announces Publication of Latest Peer-Reviewed Protocol Paper Reporting on its Accelerating Dementia Pathway (ADePT) Project

*The Use of a Computerized Cognitive Assessment to Improve the Efficiency of Primary Care Referrals to Memory Services: Protocol for the ADePT Project*

VANCOUVER, BC, April 7, 2022 /CNW/ - **Cognetivity Neurosciences Ltd. (the "Company" or "Cognetivity")** (CSE: CGN) (OTCQB: CGNSF) (FWB: 1UB), a technology company that has created a cognitive testing platform for use in medical, commercial and consumer environments, is pleased to announce that the protocol and interim results of its Accelerating Dementia Pathway Technologies Study (the "**AdePT Study**") has been published in the Journal of Medical Internet Research, which is a leading peer-reviewed journal for digital health.

Cognetivity initiated the AdePT Study and it was funded by Innovate UK, which is the United Kingdom's innovation agency that provides money and support to organizations in order to for them make new products and services. The project was developed to generate the real-world evidence basis to support the adoption of the Company's Integrated Cognitive Assessment ("**CognICA™**") as an inexpensive screening tool for the detection of cognitive impairment and improvement of the efficiency of the dementia care pathway in the UK.

The data collection for the project has also recently been completed and the interim analysis of the data indicates a significant level of direct cost savings to the National Health Service as well as better clinical outcomes. The aim of the project was to improve the efficiency of the dementia pathway at its beginning and support systems integration at the intersection between primary and secondary care.

The introduction of CognICA™ as a standardized, self-administered, digital assessment tool for the timely detection of neurodegeneration as part of a decision-support system can reduce unnecessary referrals, reduce service backlogs and reduce assessment variability. To view the publication, please navigate to the following website: <https://www.researchprotocols.org/2022/1/e34475>

## **About the Journal of Medical Internet Research**

The Journal of Medical Internet Research ("**JMIR**") is a peer-reviewed open-access medical journal established in 1999 covering eHealth and "healthcare in the Internet age". JMIR is the leading peer-reviewed journal for digital medicine and health and healthcare in the internet age.

## **About Cognetivity Neurosciences Ltd.**

Cognetivity is a technology company that has created a cognitive testing platform for use in medical, commercial and consumer environments. Cognetivity's CognICA™ uses Artificial Intelligence and machine learning techniques to help detect the earliest signs of cognitive impairment by testing the performance of large areas of the brain. The CognICA™ is currently available for clinical use in the USA, UK and Europe, with regulatory approval for other regions planned for 2022.

ON BEHALF OF THE BOARD OF DIRECTORS

"Sina Habibi"

Sina Habibi

Chief Executive Officer and Director

## FORWARD-LOOKING STATEMENTS

Certain statements included in this news release constitute forward-looking information or statements (collectively, "forward-looking statements"), including those identified by the expressions "anticipate", "assume", "believe", "plan", "estimate", "expect", "intend", "may", "should" and similar expressions to the extent they relate to the Company or its management. The forward-looking statements are not historical facts but reflect current expectations regarding future results or events. This news release contains forward looking statements. These forward-looking statements are not guarantees of future performance and involve risks, uncertainties and assumptions which are difficult to predict. Such statements are based on current expectations and various estimates, factors and assumptions and involve known and unknown risks, uncertainties and other factors. Such statements and information are based on numerous assumptions regarding present and future business strategies and the environment in which the Company will operate in the future. The Company assumes no responsibility to update or revise forward-looking information to reflect new events or circumstances unless required by law. Readers should not place undue reliance on the Company's forward-looking statements.

The Canadian Securities Exchange does not accept responsibility for the adequacy or accuracy of this release.

SOURCE Cognetivity Neurosciences Ltd.

View original content: <http://www.newswire.ca/en/releases/archive/April2022/07/c1742.html>

%SEDAR: 00039034E

**For further information:** For more information, please visit: [www.cognetivity.com](http://www.cognetivity.com) or contact: [info@cognetivity.com](mailto:info@cognetivity.com); For media enquiries, please contact: Josh Stanbury | [josh@sjspr.co](mailto:josh@sjspr.co) | 416-628-7441

CO: Cognetivity Neurosciences Ltd.

CNW 09:00e 07-APR-22